Compare Main Street Capital Corporation (MAIN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs GeneDx Holdings Corp — how do they compare? Main Street Capital Corporation trades at $58.32 (market cap $5.52B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Main Street Capital Corporation is far larger — about 2.3× GeneDx Holdings Corp's market cap, and Main Street Capital Corporation pays a 5.39% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MAIN | WGS | |
|---|---|---|
Market Cap | $5.52B | $2.44B |
Sector | Financials | Technology |
52-Week High | $67.54 | $167.51 |
52-Week Low | $49.63 | $34.51 |
Dividend Yield | 5.39% | — |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $58.51, slightly below the consensus price target of $56.67, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings of $0.97 per share missed expectations. Recent dividend announcements and portfolio appreciation highlight MAIN's income-focused strategy in the BDC sector.
MAIN presents a stable income opportunity with consistent dividends, but faces headwinds from higher expenses impacting recent earnings. The stock's current valuation at 11.85x P/E appears reasonable, though investor caution is warranted given the majority hold rating from analysts and competitive pressures in the private credit market.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
